Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 3/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4586803 | 1.00 | CPA1 (0.43) | CPA1PIN1CTSLNPC1TP53 | |
| SCHEMBL4588152 | 0.81 | PTGS2 (0.35) | — | |
| SCHEMBL4587407 | 0.78 | ALDH1A1 (0.42) | KMT2A | |
| SCHEMBL23628394 | 0.70 | CTSL (0.50) | PIN1CTSLNPC1RAB9ACYP3A4 | |
| SCHEMBL12115589 | 0.70 | ACACB (0.60) | PIN1CTSLNPC1RAB9ACYP3A4 | |
| SCHEMBL596491 | 0.69 | MME (0.59) | CPA1 | |
| SCHEMBL596493 | 0.69 | MME (0.59) | CPA1 | |
| SCHEMBL4588667 | 0.69 | EPHX1 (0.53) | CPA1 | |
| SCHEMBL13192099 | 0.69 | CTSL (0.55) | PIN1CTSLNPC1RAB9ACYP3A4 | |
| SCHEMBL22321660 | 0.68 | PIN1 (0.51) | PIN1CTSLNPC1RAB9ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | CPA1 1263/4885PIN1 1234/4885CTSL 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.